ERBB2 and breast carcinoma: Concurring with these findings, in independent studies metformin showed decreased cell proliferation in insulin resistant, luminal B subtype breast cancer patients although overall metformin did not significantly alter cell proliferation in this patient cohort [102] and diabetic patients with HER2+ subtype had a better prognosis with metformin [115].